Articles from Prothena Corporation plc
Prothena Announces Board of Directors Update
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Oleg Nodelman will step down from Prothena’s Board of Directors to create time to focus on existing and new endeavors. During his five-year tenure, Mr. Nodelman played a pivotal role in which he made significant contributions to the Company’s current strategy.
By Prothena Corporation plc · Via Business Wire · December 30, 2024
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Prothena Corporation plc (NASDAQPRTA), today announced results from the Phase IIb PADOVA study conducted by partner Roche investigating prasinezumab in 586 people with early-stage Parkinson’s disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical effect in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01] and p=0.0657. The effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99] and nominal p=0.0431. Pre-specified supplementary covariate-adjusted* analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81 [0.67-0.98]; nominal p=0.0334) and in the levodopa subgroup (HR=0.76 [0.61-0.95]; nominal p=0.0175). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Prasinezumab continues to be well tolerated and no new safety signals were observed in the study.
By Prothena Corporation plc · Via Business Wire · December 19, 2024
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2024 and provided business highlights.
By Prothena Corporation plc · Via Business Wire · November 12, 2024
Prothena to Report Third Quarter 2024 Financial Results on November 12
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024, after the close of the U.S. financial markets.
By Prothena Corporation plc · Via Business Wire · November 5, 2024
Prothena Announces Leadership Team Updates
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothena’s executive leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Hideki Garren, M.D., Ph.D., will pursue an opportunity at a large pharmaceutical company to lead a global product development division. Prothena will initiate a search for a world-class healthcare leader as our next Chief Medical Officer.
By Prothena Corporation plc · Via Business Wire · September 27, 2024
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences:
By Prothena Corporation plc · Via Business Wire · August 29, 2024
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2024 and provided business highlights.
By Prothena Corporation plc · Via Business Wire · August 8, 2024
Prothena to Report Second Quarter 2024 Financial Results on August 8
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets.
By Prothena Corporation plc · Via Business Wire · August 1, 2024
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
By Prothena Corporation plc · Via Business Wire · May 28, 2024
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided business highlights.
By Prothena Corporation plc · Via Business Wire · May 8, 2024
Prothena to Report First Quarter 2024 Financial Results on May 8
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
By Prothena Corporation plc · Via Business Wire · May 1, 2024
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia & Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies.
By Prothena Corporation plc · Via Business Wire · April 15, 2024
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences:
By Prothena Corporation plc · Via Business Wire · March 5, 2024
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company’s vision and overall growth strategy.
By Prothena Corporation plc · Via Business Wire · March 4, 2024
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board’s regular succession planning.
By Prothena Corporation plc · Via Business Wire · February 21, 2024
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2023. In addition, the Company provided 2024 financial guidance and business highlights.
By Prothena Corporation plc · Via Business Wire · February 15, 2024
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.
By Prothena Corporation plc · Via Business Wire · February 8, 2024
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, provided a business update on portfolio programs.
By Prothena Corporation plc · Via Business Wire · January 8, 2024
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.
By Prothena Corporation plc · Via Business Wire · November 2, 2023
Prothena to Report Third Quarter 2023 Financial Results on November 2
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2023 financial results on Thursday, November 2, 2023 after the close of the U.S. financial markets.
By Prothena Corporation plc · Via Business Wire · October 26, 2023
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences:
By Prothena Corporation plc · Via Business Wire · August 31, 2023
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2023 and provided business highlights.
By Prothena Corporation plc · Via Business Wire · August 3, 2023
Prothena to Report Second Quarter 2023 Financial Results on August 3
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2023 financial results on Thursday, August 3, 2023 after the close of the U.S. financial markets.
By Prothena Corporation plc · Via Business Wire · July 27, 2023
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today shared data on three investigational product programs for the treatment and prevention of Alzheimer’s disease, PRX005, PRX012 and PRX123, at the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.
By Prothena Corporation plc · Via Business Wire · July 17, 2023
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually. Participation includes three posters highlighting the company’s next generation therapies for Alzheimer’s disease and a Prothena sponsored symposium.
By Prothena Corporation plc · Via Business Wire · July 11, 2023
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005 and will pay Prothena $55 million. PRX005, which is designed to be a best-in-class anti-tau antibody, specifically targets an area within the microtubule binding region (MTBR) of tau for the potential treatment of Alzheimer’s disease.
By Prothena Corporation plc · Via Business Wire · July 10, 2023
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication of the Phase 3 VITAL clinical trial in Blood, a journal of the American Society of Hematology (ASH). The published data demonstrate that in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis, a statistically significant survival benefit of 74 percent was observed for those treated with birtamimab plus standard of care (SOC) versus 49 percent in patients on placebo plus SOC at 9 months (HR 0.413, p=0.021). All participants in the clinical trial received concomitant bortezomib-containing chemotherapy regimens as part of SOC.
By Prothena Corporation plc · Via Business Wire · June 27, 2023
Prothena to Participate in Jefferies 2023 Healthcare Conference
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 1:00 pm ET.
By Prothena Corporation plc · Via Business Wire · June 2, 2023
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Billy Dunn, M.D., to its Board of Directors. Dr. Dunn is the founding and former Director of the Office of Neuroscience, Center for Drug Evaluation and Research (CDER), at the U.S. Food and Drug Administration (FDA).
By Prothena Corporation plc · Via Business Wire · May 16, 2023
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2023 and provided business highlights.
By Prothena Corporation plc · Via Business Wire · May 4, 2023
Prothena to Report First Quarter 2023 Financial Results on May 4
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023 after the close of the U.S. financial markets.
By Prothena Corporation plc · Via Business Wire · April 27, 2023
Prothena to Participate in 2023 Bank of America Healthcare Conference
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on Tuesday, May 9, 2023 at 9:20 AM PT.
By Prothena Corporation plc · Via Business Wire · April 24, 2023
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (Aβ) product candidate in development for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Gothenburg, Sweden.
By Prothena Corporation plc · Via Business Wire · March 31, 2023
Prothena to Participate in Stifel 2023 Virtual CNS Days
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday March 28, 2023 at 10:30 AM ET.
By Prothena Corporation plc · Via Business Wire · March 21, 2023
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena's leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.
By Prothena Corporation plc · Via Business Wire · March 14, 2023
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2022. In addition, the Company provided 2023 financial guidance and business highlights.
By Prothena Corporation plc · Via Business Wire · February 23, 2023
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.
By Prothena Corporation plc · Via Business Wire · February 16, 2023
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 85,000 ordinary shares of the Company. The option has an exercise price per share equal to $53.67, which was the closing trading price on February 1, 2023, the date of the grant. The option will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grant and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The option was granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
By Prothena Corporation plc · Via Business Wire · February 3, 2023
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms. PRX005 is one of three programs in the global neuroscience research and development collaboration between Prothena and Bristol Myers Squibb.
By Prothena Corporation plc · Via Business Wire · January 31, 2023
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 487,500 of its ordinary shares.
By Prothena Corporation plc · Via Business Wire · December 14, 2022
Prothena Announces Proposed Public Offering of Ordinary Shares
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold.
By Prothena Corporation plc · Via Business Wire · December 13, 2022
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis, a statistically significant survival benefit was observed in those treated with birtamimab at 9 months. The survival benefit of birtamimab in VITAL remained consistent across all key baseline variables in patients with Mayo Stage IV AL amyloidosis. The data were presented in an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.
By Prothena Corporation plc · Via Business Wire · December 12, 2022
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $40 million milestone payment from Novo Nordisk related to the continued advancement of NNC6019 (formerly PRX004) in a Phase 2 clinical study for the treatment of ATTR cardiomyopathy. There remains a high unmet medical need in moderate to advanced ATTR amyloidosis patients at high risk for early mortality due to amyloid deposition in vital organs.
By Prothena Corporation plc · Via Business Wire · November 21, 2022
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2022 and provided a business update.
By Prothena Corporation plc · Via Business Wire · November 3, 2022
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at the American Society of Hematology Conference 2022 (ASH). The meeting will be held December 10-13, 2022 in New Orleans, LA.
By Prothena Corporation plc · Via Business Wire · November 3, 2022
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQPRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets.
By Prothena Corporation plc · Via GlobeNewswire · October 27, 2022